- Primary research
- Open Access
hsa_circ_0081143 promotes cisplatin resistance in gastric cancer by targeting miR-646/CDK6 pathway
© The Author(s) 2019
- Received: 19 October 2018
- Accepted: 21 January 2019
- Published: 1 February 2019
Increasing studies indicated that circRNAs play critical roles in tumor progression. However, the roles and underlying mechanisms of circRNAs in gastric cancer (GC) remain largely unclear.
Microarray assay was used to screen the abnormally expressed circRNAs in GC. Cell viability assay, transwell assay and in vivo assay were performed to assess the effects of hsa_circ_0081143 on GC cells. Next, interaction between hsa_circ_0081143 and miR-646 was detected by luciferase reporter assay and RNA pull-down assay.
High throughput microarray assay showed that hsa_circ_0081143 was upregulated in GC tissues, which was further confirmed by qRT-PCR. Correlation analysis showed that high hsa_circ_0081143 expression was associated with the advanced TNM stage, lymphnode metastases, and poor overall survival of GC patients. Hsa_circ_0081143 inhibition decreased GC cells viability, invasion ability and induced the sensitivity of GC cells to cisplatin (DDP) in vitro. Mechanistically, we showed that hsa_circ_0081143 could act as an endogenous sponge by directly binding to miR-646 and downregulation of miR-646 efficiently reversed the inhibition of CDK6 induced by hsa_circ_008114 knockdown. Additionally, hsa_circ_0081143 silencing suppressed the tumorigenesis and remarkably enhance DDP inhibitory effects of GC cells in vivo.
Our study indicated a novel regulatory loop that hsa_circ_0081143/miR-646/CDK6 axis in GC progression. These data suggested that hsa_circ_0081143 might act as a potential novel therapeutic strategy for GC treatment.
- Gastric cancer
Gastric cancer (GC) is one of the leading causes of cancer-related death worldwide, particularly in China [1, 2]. Currently, surgical resection is still the main option for treating GC . Although therapeutic strategies have been developed and widely used in the past several decades, GC patients’ prognosis still remains unsatisfactory due to metastasis and chemoresistance [4, 5]. Diaminodichloroplatinum (cisplatin, DDP) is one of the most effective and widely used DNA-damaging anticancer drugs used for cancer treatment . Therefore, it is of great significance to identify new diagnostic biomarkers and more effective therapeutic approaches for the treatment of GC.
Circular RNAs (circRNAs) are a type of covalently closed loop structure of endogenous RNAs, which are characterized by linking the 3′ and 5′ ends generated by back splicing [7, 8]. Recently, increasing studies showed that circRNAs could play critical regulatory roles in differentiation, proliferation, invasion and apoptosis [9, 10]. For example, Zong et al.  showed that circRNA_102231 was significantly increased and promoted lung cancer cells proliferation and invasion in vitro. Li et al.  showed that circFGFR4 promoted differentiation of myoblasts via binding miR-107 to relieve its inhibition of Wnt3a. Jin et al.  found that circHIPK3 served as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. These reports suggested that circRNAs could be valuable diagnostic and therapeutic strategies in GC. Nevertheless, the biological function and underlying mechanisms of circRNAs in GC remain to be further studied.
In the present study, high throughput microarray assay showed that hsa_circ_0081143 was upregulated in GC tissues, which was reported in a previous study . High hsa_circ_0081143 expression was significantly increased and associated with advanced clinical features and poor overall survival of GC patients. Subsequently, we explored the molecular mechanism underlying hsa_circ_0081143 deregulation in GC progression, we identified that hsa_circ_0081143 promoted GC progression via the hsa_circ_0081143-miR-646-CDK6-KLF5 signaling axis, suggesting hsa_circ_0081143 might act as a potential therapeutic target for GC treatment.
Patients and methods
Correlation between hsa_circ_0081143 expression and clinical features of GC patients
Tumor size (cm)
Moderate + poor
I + II
III + IV
Lymph node metastasis
Human circular RNA microarray
After being obtained from surgical specimens, samples (3 pairs of GC tissues and adjacent non-tumor tissues) were immediately frozen using liquid nitrogen. Sample preparation and microarray hybridization were performed according to the protocols of Arraystar (Rockville, MD, USA). The circRNAs chip containing 5396 probes specific for human circular RNAs splicing sites was used. Total RNA was extracted, and digested with Rnase R kit (Epicentre, Madison, WI) to remove linear RNA. Human circRNA microarray hybridization was performed according to Arraystar standard protocols. The enriched circRNA was amplified to cDNA, and transcribed into cRNA using Arraystar Super RNA Labeling Kit (Arraystar, Rockville, MD). Labeled cRNAs were then hybridized using Arraystar Human circRNA Array (8 × 15 K, Arraystar) and scanned by the Agilent Scanner G2505C (Jamul, CA, USA). CircRNAs demonstrating fold-changes of ≥ 2 and P-values of < 0.05 were regarded as significantly differentially expressed.
Cell culture and transfection
Human GC cell lines SGC7901, MGC803 and Human gastric epithelial cell line (GES1) was purchased from Biochemistry and Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The DDP-resistant SGC7901/DDP cells and MGC803/DDP cells are purchased the KeyGen (Nanjing, China). All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco, Carlsbad, CA, USA) supplemented with 10% FBS, 100 U/ml penicillin, and 0.1 mg/ml streptomycin in a 37 °C humidified incubator with 5% CO CO2.
The small interfering RNAs (siRNAs) specifically targeting has-circ_0081143 (si- circ_0081143) and scrambled negative control siRNA (si-NC) were obtained from RiboBio (Guangzhou, China). Expression plasmids pcDNA3.0 (Invitrogen) were then constructed and sequenced for the ectopic expression of CDK6 (pcDNA-CDK6). MiR-646 mimics, miR-646 inhibitors and NC mimics and NC inhibitors were designed and synthesized by Gene-Pharma (Shanghai, China). The cells were transfected with RNA oligoribonucleotides or constructs using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol.
Cell viability assays
Cell proliferation was measured by Cell Counting Kit-8 (CCK-8, Roche, Basel, Switzerland) following the manufacturer’s instructions. Cells (2 × 103/well) were seeded into 96-well plates (Corning, NY, USA) and incubated for 24 h, 48 h, and 72 h, respectively. 10 μL of CCK-8 regents were added into cells and incubated for 2 h at 37 °C. The absorbance was measured at 450 nm on the spectrophotometer.
Colony formation assay was conducted for 14 days, and the colonies were fixed in 70% ethanol for 10 min and then stained with 1% crystal violet solution for another 10 min at room temperature. Images were captured with a camera (Nikon, Japan).
For cell cycle analysis, GC cells (2 × 105 cells) were fixed overnight at 4 °C in 70% ethanol. Then, cells washed with PBS and treated with propidium iodide (PI, 0.05 mg/mL, Sigma, MO, USA) for 20 min at room temperature. Cell cycle analysis was used with FACS flow cytometry (BD Biosciences, NJ, USA).
Cell apoptosis was analyzed with Annexin V-FITC Apoptosis Kit (Biovision, CA, USA) according to the manufacturer’s instructions. After the labeling, Cells were analyzed with FACS flow cytometry (BD Biosciences).
Transwell invasion assay
The invasion ability was assessed using 6.5-mm transwell chambers with a pore size of 8 μm (Costar, Corning, NY, USA). Cells (2 × 105) were suspended in 100 μL serum-free medium and seeded into the upper chamber or precoated with 80 μL of Matrigel solution (BD, NJ, USA) for cell invasion assay. The lower chamber was filled with 600 μL of 10% FBS medium. After incubation for 48 h, cells that had invaded to the lower side of the membrane were fixed and stained with crystal violet. Five random fields were chosen to count and take photos under a microscope.
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from tissues or cell lines using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s protocol. Then, the reverse transcription was done with a Reverse Transcription Kit (Takara, Tokyo, Japan). Real-time PCR analysis was performed with SYBR Green (Takara). The amounts of expression level were calculated by the 2−ΔΔCt method and the relative expression level was normalized to the expression of GAPDH (for circRNAs and mRNAs) or U6 (for miRNAs). QRT-PCR reactions were performed by the ABI7500 system (Applied Biosystems, Shanghai, China).
Western blot analysis
Cells were lysed using RIPA protein extraction reagent (Beyotime, Shanghai, China) supplemented with PMSF (Roche, Basel, Switzerland) and 1% protease inhibitors. The protein concentration is quantified by BCA protein assay kit (Pierce, Rockford, IL, USA). Proteins were separated by 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride (PVDF membranes. The membranes were then incubated with primary antibodies (Cell Signaling Technology, MA, USA) at 4 °C overnight, followed by reaction with corresponding secondary antibody. Chemiluminescence was detected using the ECL kit (Beyotime, China). GAPDH antibody was used as an internal control.
Formalin-fixed, paraffin-embedded tissue sections were used for the immunohistochemical analysis. Paraffin was removed from the tissues and the sections were hydrated through a graded series of ethanol. Antigen retrieval was and sections were blocked with 5% sheep serum for 60 min. Sections were incubated with antibody (Abcam) overnight at 4 °C. Then signals were visualized with 3,3′-diaminobenzidine on the second day.
Luciferase reporter assay
A hsa_circ_0081143 segment was synthesized with either mutant or wild type (Wt) seed region and cloned into the psiCHECK-2 vector. Cells (1 × 105 cells/well) were co-transfected with circ_0081143-Wt or circ_0081143-Mut and miR-646 mimics or miR-NC using Lipofectamine 2000 (Invitrogen). After induction for 48 h, luciferase activity was assessed using the dual-luciferase reporter kit (Promega, Madison, WI, USA). A wild-type 3′-UTR fragment of CDK6 (CDK6-Wt) and mutant CDK6 -3′UTR mRNA containing the putative miR-646 binding site was amplified by PCR and cloned into downstream of the firefly luciferase gene in the pMIR-REPORT vector (Thermo Scientific, Waltham, MA, USA). For the luciferase assay, cells were co-transfected in 48-well plates with CDK6-Wt or CDK6-Mut, miR-646 mimics or miR-NC mimics using Lipofectamine 2000 reagents.
RNA pull-down assay
RNAs were labeled with biotin using Pierce RNA 3′ End Desthiobiotinylation Kit (Thermo Scientific) according to the manufacturer’s protocols. Then biotin-labeled wild-type miR-646 and negative control (mutant miR-646) were incubated with cell lysates, as well as Magnetic beads. After incubation for 6 h, the precipitated RNAs on beads were eluted and extracted, followed by qRT-PCR examination.
In vivo assay
5-week-old female athymic BALB/c mice were maintained under specific pathogen-free conditions and manipulated according to protocols approved by the animal center of Xinxiang Medical University. They were randomly divided into the following groups: (a) si-NC + PBS; (b) si-circ_0081143 + PBS; (c) si-NC + DDP; (d) si-circ_0081143 + DDP. When the tumors were palpable, DDP (5 mg/kg) was peritoneally injected into the mice every 4 days. Tumor volumes were examined every week when the implantations were starting to grow bigger. All mice were killed 6 weeks after injection.
The statistical analysis was carried out by utilizing SPSS 20.0 statistical software. Data was represented as mean ± the standard deviation (SD). The significance of differences between groups was estimated by two-side student’s t-test, χ2 test or ANOVA as appropriate. P < 0.05 was considered as significant.
Hsa_circ_0081143 is upregulated in GC
Hsa_circ_0081143 promote GC cells progression
Next, we determine the effect of hsa_circ_0081143 on carcinogenesis in vivo, we established xenograft mouse models by subcutaneously injecting MGC803 cells transfected with si-circ_0081143 or si-NC. As shown in Fig. 2g, h, has-circ_0081143 suppression resulted in a smaller size of the subcutaneous tumor in mice, and intraperitoneal injection of cisplatin into the mice with si-circ_0081143 further inhibited the growth of tumor. As expected, the average tumor weight statistic of excised tumor showed a similar trend to tumor volume (Fig. 2i).
Hsa_circ_0081143 directly contact with miR-646
CDK6 is target of miR-646 in GC
Hsa_circ_0081143 regulates CDK6 expression by competing for miR-646
Recently, increasing evidence indicated that circRNAs play critical roles in GC progression. For example, Chen et al.  showed that hsa_circ_0000190 expression was downregulated and associated with advanced tumor progression and poor overall survival of GC patients. Sun et al.  showed that circPVRL3 suppression promoted the proliferation and migration of GC cells. Zhang et al.  showed that circular RNA_LARP4 inhibited GC cells proliferation and invasion by regulating miR-424-5p/LATS1 axis. However, the expression and underlying mechanism of circRNAs in GC tumorigenesis remain largely unclear.
In the present study, we showed that has-circ_0081143 expression was remarkably increased and correlated with advanced TNM stage, lymphnode metastasis, and poor overall survival in GC patients. QRT-PCR showed that hsa_circ_0081143 expression was significantly increased in SGC7901/DDP and MGC803/DDP cells. Furthermore, we explored the roles of hsa_circ_0081143 on GC progression. Results showed that hsa_circ_0081143 promoted GC cells proliferation, invasion, and reduced the sensitivity of GC cells to cisplatin in vitro. In addition, in vivo assays revealed that hsa_circ_0081143 suppression reduced GC cells growth and enhanced sensitivity of GC cells to cisplatin. These data indicated that hsa_circ_0081143 might exhibit an oncogene-like function in the modulation of GC progression.
As revealed by more and more evidences, circRNAs could act as competing endogenous RNAs (ceRNA) to compete for miRNAs, thereby negatively modulating miRNA expression . Through online software miRBase and circinteractome, miR-646 was identified as a potential target of hsa_circ_0081143. Hsa_circ_0081143 inhibition significantly increased miR-646 expression in GC cells. Luciferase reporter assay revealed that miR-646 mimics significantly decreased the activity of circ_0081143-Wt in GC cells. Pull-down assay further showed that hsa_circ_0081143 expression was significantly enriched by biotin-miR-646 in GC cells. Previous studies showed that miR-646 exhibited a tumor suppressor role in human tumors. For example, Sun et al.  showed that miR-646 suppressed osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2). Pan et al.  showed that miR-646 decreased cell proliferation and metastasis by EGFR pathway in lung cancer. Recently, Zhang et al.  revealed that miR-646 inhibited GC cells proliferation and EMT progression by targeting FOXK1. In the present study, our data showed that miR-646 expression was significantly decreased and negatively correlated with hsa_circ_0081143 levels in GC tissues. Kaplan–Meier Plotter revealed that low miR-646 expression was correlated with poor overall survival of GC patients. These data suggested that hsa_circ_0081143 could act as an endogenous sponge to modulate the expression and function of miR-646 in GC progression.
Cell division protein kinase 6 (CDK6), a member of the CDK family, which play critical roles in cell cycle progression, apoptosis, cancer invasion, metastasis, and chemoresistance [23, 24]. For example, Lu et al.  showed that miRNA-186 inhibited prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6. Zhu et al.  found that miR-145 sensitized ovarian cancer cells to paclitaxel by targeting Sp1 and CDK6. Moreover, Deng et al.  found that miR-218 suppressed GC cells cycle progression through CDK6/Cyclin D1/E2F1 axis. However, the roles of CDK6 expression in GC progression remain unclear. In our mechanistic research, CDK6 was identified as a direct target for miR-646 in GC. Notably, recently some studies pointed out that circRNAs are also implicated in the modulation of CDK6 in human malignances [28–30]. We therefore examined whether hsa_circ_0081143 could affect the expression of CDK6 in GC. As expected, in this study, a positive association between hsa_circ_0081143 and CDK6 was found in GC specimens. CDK6 was found to be positively regulated by hsa_circ_0081143, indicating that CDK6 could be a downstream effector in the hsa_circ_0081143-miR-646 axis. Moreover, rescue experiments further revealed the antagonistic roles of si_circ_0081143 and CDK6 in the modulation of carcinogenic properties of GC cells. Taken together, these data indicated that hsa_circ_0081143/miR-646/CDK6 signaling pathway play important roles in GC progression.
In the present study, we verified that the knockdown of hsa_circ_0081143 reduced the proliferation, invasion, and cisplatin resistance in GC cells. More importantly, we suggested that hsa_circ_0081143 might act as a ceRNA to inhibit the expression and activity of miR-646, resulting in elevated expression of CDK6. Overall, our findings revealed that hsa_circ_0081143 might serve as an effective therapeutic candidate for GC treatment.
GYL and MHX designed the study. DYL, MHX, XJF, and LLW wrote the manuscript. DYL, MHX revised the manuscript. DYL, MHX, XJF, LLW, YHJ and ZQ performed experiments. DYL, LLW and ZQ collected the clinical data and performed data analysis. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Availability of data and materials
The significance of differences between groups was estimated by two-side student’s t-test, χ2 test or ANOVA as appropriate.
Consent for publication
All authors agree to submit this manuscript and declare no competing of interest related to this work.
Ethics approval and consent to participate
This experiment was approved by ethic committee of the First Affiliated Hospital of Xinxiang Medical University, and the tissues were acquired with the consent of patients.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.PubMedView ArticleGoogle Scholar
- Rugge M, Fassan M, Graham DY. Epidemiology of gastric cancer[M]//Gastric Cancer. Cham: Springer; 2015. p. 23–34.Google Scholar
- de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin. 2013;42(2):219–40.View ArticleGoogle Scholar
- Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric cancer. 2011;14(2):113–23.View ArticleGoogle Scholar
- Liu L, Ning X, Sun L, et al. Hypoxia-inducible factor-1α contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 2008;99(1):121–8.PubMedGoogle Scholar
- Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293–8.PubMedView ArticleGoogle Scholar
- Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453.PubMedPubMed CentralView ArticleGoogle Scholar
- Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 2015;22(3):256.PubMedView ArticleGoogle Scholar
- Chen LL. The biogenesis and emerging roles of circular RNAs. Nat Rev Mol Cell Biol. 2016;17(4):205.PubMedView ArticleGoogle Scholar
- You X, Vlatkovic I, Babic A, et al. Neural circular RNAs are derived from synaptic genes and regulated by development and plasticity. Nat Neurosci. 2015;18(4):603.PubMedPubMed CentralView ArticleGoogle Scholar
- Zong L, Sun Q, Zhang H, et al. Increased expression of circRNA_102231 in lung cancer and its clinical significance. Biomed Pharmacother. 2018;102:639–44.PubMedView ArticleGoogle Scholar
- Li H, Wei X, Yang J, et al. circFGFR4 promotes differentiation of myoblasts via binding miR-107 to relieve its inhibition of Wnt3a. Mol Ther Nucleic Acids. 2018;11:272–83.PubMedPubMed CentralView ArticleGoogle Scholar
- Jin P, Huang Y, Zhu P, et al. CircRNA circHIPK3 serves as a prognostic marker to promote glioma progression by regulating miR-654/IGF2BP3 signaling. Biochem Biophys Res Commun. 2018;503:1570–4.PubMedView ArticleGoogle Scholar
- Dang Y, Ouyang X, Zhang F, et al. Circular RNAs expression profiles in human gastric cancer. Sci Rep. 2017;7(1):9060.PubMedPubMed CentralView ArticleGoogle Scholar
- Dudekula DB, Panda AC, Grammatikakis I, et al. CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 2016;13(1):34–42.PubMedView ArticleGoogle Scholar
- Chen S, Li T, Zhao Q, et al. Using circular RNA hsa_circ_0000190 as a new biomarker in the diagnosis of gastric cancer. Clin Chim Acta. 2017;466:167–71.PubMedView ArticleGoogle Scholar
- Sun HD, Xu ZP, Sun ZQ, et al. Down-regulation of circPVRL3 promotes the proliferation and migration of gastric cancer cells. Sci Rep. 2018;8(1):10111.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhang J, Liu H, Hou L, et al. Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer. 2017;16(1):151.PubMedPubMed CentralView ArticleGoogle Scholar
- Kulcheski FR, Christoff AP, Margis R. Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J Biotechnol. 2016;238:42–51.PubMedView ArticleGoogle Scholar
- Sun X, Geng X, Zhang J, et al. miRNA-646 suppresses osteosarcoma cell metastasis by downregulating fibroblast growth factor 2 (FGF2). Tumor Biol. 2015;36(3):2127–34.View ArticleGoogle Scholar
- Pan Y, Chen Y, Ma D, et al. miR-646 is a key negative regulator of EGFR pathway in lung cancer. Exp Lung Res. 2016;42(6):286–95.PubMedView ArticleGoogle Scholar
- Zhang P, Tang WM, Zhang H, et al. MiR-646 inhibited cell proliferation and EMT-induced metastasis by targeting FOXK1 in gastric cancer. Br J Cancer. 2017;117(4):525.PubMedPubMed CentralView ArticleGoogle Scholar
- Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors. Cancer Discov. 2016. https://doi.org/10.1158/2159-8290.CD-16-0095.PubMedView ArticleGoogle Scholar
- Chen-Kiang S, Di Liberto M, Huang X. Targeting CDK4 and CDK6 in cancer therapy: U.S. Patent 9,259,399[P]. 2016-2-16.Google Scholar
- Lu S, Wang MS, Chen PJ, et al. miRNA–186 inhibits prostate cancer cell proliferation and tumor growth by targeting YY1 and CDK6. Exp Ther Med. 2017;13(6):3309–14.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhu X, Li Y, Xie C, et al. miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer. 2014;135(6):1286–96.PubMedView ArticleGoogle Scholar
- Deng M, Zeng C, Lu X, et al. miR-218 suppresses gastric cancer cell cycle progression through the CDK6/Cyclin D1/E2F1 axis in a feedback loop. Cancer Lett. 2017;403:175–85.PubMedView ArticleGoogle Scholar
- Gong Y, Mao J, Wu D, et al. Circ-ZEB1. 33 promotes the proliferation of human HCC by sponging miR-200a-3p and upregulating CDK6. Cancer Cell Int. 2018;18(1):116.PubMedPubMed CentralView ArticleGoogle Scholar
- Zhong Z, Lv M, Chen J. Screening differential circular RNA expression profiles reveals the regulatory role of circTCF25-miR-103a-3p/miR-107-CDK6 pathway in bladder carcinoma. Sci Rep. 2016;6:30919.PubMedPubMed CentralView ArticleGoogle Scholar
- Chen L, Zhang S, Wu J, et al. circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family. Oncogene. 2017;36(32):4551.PubMedPubMed CentralView ArticleGoogle Scholar